GC
BBIO icon

Guggenheim Capital’s BridgeBio Pharma BBIO Stock Holding History

Guggenheim Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.81M Sell
37,672
-2,489
-6% -$174K 0.02% 622
2026
Q1 		$2.98M Buy
40,161
+5,427
+16% +$393K 0.02% 579
2025
Q4 		$2.66M Sell
34,734
-5,258
-13% -$345K 0.02% 591
2025
Q3 		$2.08M Sell
39,992
-4,944
-11% -$241K 0.02% 671
2025
Q2 		$1.94M Sell
44,936
-2,188
-5% -$79.6K 0.02% 665
2025
Q1 		$1.63M Buy
47,124
+2,463
+6% +$83K 0.02% 699
2024
Q4 		$1.23M Sell
44,661
-6,340
-12% -$164K 0.01% 824
2024
Q3 		$1.3M Buy
51,001
+1,425
+3% +$37.4K 0.01% 982
2024
Q2 		$1.26M Sell
49,576
-760
-2% -$20.8K 0.01% 1002
2024
Q1 		$1.56M Buy
50,336
+9,508
+23% +$323K 0.01% 993
2023
Q4 		$1.65M Buy
+40,828
New +$1.23M 0.01% 925
2022
Q1 		– Sell
-59,838
Closed -$999K – 2124
2021
Q4 		$999K Buy
59,838
+8,739
+17% +$370K 0.01% 1373
2021
Q3 		$2.4M Buy
51,099
+5,350
+12% +$287K 0.01% 966
2021
Q2 		$2.79M Buy
+45,749
New +$2.61M 0.02% 921

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Guggenheim Capital's BBIO Position: Q2 2026 in Review

Guggenheim Capital reduced its BridgeBio Pharma (BBIO) stake by 6.2% in Q2 2026, selling an estimated $174K and leaving 37,672 shares worth $2.81M. The position accounts for 0.02% of the portfolio, ranked #622.

Guggenheim Capital first reported a position in BBIO in Q2 2021 and has held it in 14 quarters since. The position peaked at $2.98M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Guggenheim Capital held 37,672 shares of BridgeBio Pharma worth $2.81M as of Q2 2026.
  • Guggenheim Capital sold 2,489 BridgeBio Pharma shares in Q2 2026, an estimated $174K.
  • BridgeBio Pharma made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #622 holding.
  • Guggenheim Capital first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 14 quarters since.
  • Guggenheim Capital's BridgeBio Pharma position peaked at $2.98M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.